Review
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy
Affiliations
- PMID: 16956823
Item in Clipboard
Review
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy
Haematologica.
2006 Sep.
Abstract
The aim of this review is to integrate non-exhaustive relevant data on the phenotype of human plasma cells (PC), including normal, reactive and malignant (multiple myeloma, MM) PC. This review focuses on (i) a universal marker of both normal and malignant plasma cells, CD138; (ii) markers related to malignancy i.e., CD19, CD27, CD28, and CD56; (iii) markers associated with signaling and severity of MM (CD45, CD221). Finally, this review presents data from normal PC up to human myeloma cell lines in order to: (i) define different entities of MM based on expression of CD19, CD20, CD27 and CD117; and (ii) identify new therapeutic targets.
Similar articles
-
Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.Am J Clin Pathol. 2004 Apr;121(4):482-8. doi: 10.1309/74R4-TB90-BUWH-27JX. Am J Clin Pathol. 2004. PMID: 15080299
-
CD28, a marker associated with tumoral expansion in multiple myeloma.Clin Cancer Res. 1998 Jun;4(6):1521-6. Clin Cancer Res. 1998. PMID: 9626472
-
Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.Saudi Med J. 2004 Nov;25(11):1587-92. Saudi Med J. 2004. PMID: 15573184
-
Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders.Br J Haematol. 2010 May;149(3):334-51. doi: 10.1111/j.1365-2141.2010.08121.x. Epub 2010 Mar 1. Br J Haematol. 2010. PMID: 20201947 Review.
-
Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. Cytometry B Clin Cytom. 2016. PMID: 26100534 Review.
Cited by
-
A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.Br J Cancer. 2009 Jan 27;100(2):366-9. doi: 10.1038/sj.bjc.6604839. Br J Cancer. 2009. PMID: 19165200 Free PMC article.
-
The histopathology of myeloma in the bone marrow.J Clin Exp Hematop. 2018;58(2):61-67. doi: 10.3960/jslrt.18014. J Clin Exp Hematop. 2018. PMID: 29998977 Free PMC article. Review.
-
The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability.Genome Med. 2021 Aug 9;13(1):127. doi: 10.1186/s13073-021-00938-3. Genome Med. 2021. PMID: 34372935 Free PMC article.
-
The tumor immune microenvironment in primary cutaneous melanoma.Arch Dermatol Res. 2025 Jan 18;317(1):273. doi: 10.1007/s00403-024-03758-8. Arch Dermatol Res. 2025. PMID: 39825956 Free PMC article. Review.
-
Multiple Myeloma as a Bone Disease? The Tissue Disruption-Induced Cell Stochasticity (TiDiS) Theory.Cancers (Basel). 2020 Aug 4;12(8):2158. doi: 10.3390/cancers12082158. Cancers (Basel). 2020. PMID: 32759688 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous